心力衰竭患者的腹腔外科手术和左心室辅助装置:系统性审查和元分析
Ishna Sharma1, Hayato Nakanishi2, Karl Hage1
1Department of Surgery, Mayo Clinic, Rochester, MN, USA.
American journal of surgery
|June 24, 2023
概括
代谢和减肥手术 (MBS) 与左心室辅助器件 (LVAD) 植入相结合,可以安全地将严重肥胖的患者和末期心力衰竭患者与心脏移植联系起来.
科学领域:
- 心脏病学 心脏病学
- 腹部外科 腹部外科
- 移植手术 移植手术
背景情况:
- 在严重肥胖患者中,终端心力衰竭的管理具有挑战性.
- 代谢和减肥手术 (MBS) 和左心室辅助器件 (LVAD) 植入的联合作用尚不清楚.
研究的目的:
- 评估MBS在接受LVAD植入的严重肥胖患者的安全性和有效性.
- 评估MBS作为这群人心脏移植的桥梁的作用.
主要方法:
- 通过使用来自Cochrane,Embase,PubMed和Scopus数据库的数据进行了元分析.
- 分析了11项研究,包括271名在LVAD植入期间或之后接受MBS的患者.
主要成果:
- 67.4%的患者被列为心脏移植患者,其中32.5%的心脏移植成功.
- 术后综合并发症率为47.6%,30天再入院率为23.6%,一年死亡率为10.2%.
结论:
- 与左心室辅助器件 (LVAD) 结合的代谢和减肥手术 (MBS) 是一种安全有效的策略.
- 这种综合方法可以成功地将患有严重肥胖和末期心力衰竭的患者连接到最终的心脏移植.
相关概念视频
Cardiomyopathy V: Interprofessional Care
18
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
18
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
Cardiomyopathy VII: Pre and Post Operative Nursing Management
16
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
16
Aortic Regurgitation III: Medical Management
26
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
26
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11


